nodes	percent_of_prediction	percent_of_DWPC	metapath
Salmeterol—CYP3A4—Temozolomide—brain cancer	0.207	0.324	CbGbCtD
Salmeterol—CYP3A4—Lomustine—brain cancer	0.176	0.275	CbGbCtD
Salmeterol—CYP3A5—Etoposide—brain cancer	0.109	0.171	CbGbCtD
Salmeterol—CYP2C8—Etoposide—brain cancer	0.105	0.164	CbGbCtD
Salmeterol—CYP3A4—Etoposide—brain cancer	0.0426	0.0665	CbGbCtD
Salmeterol—Cushing's syndrome—Carmustine—brain cancer	0.0119	0.0368	CcSEcCtD
Salmeterol—Hoarseness—Procarbazine—brain cancer	0.00985	0.0304	CcSEcCtD
Salmeterol—Throat sore—Lomustine—brain cancer	0.00947	0.0292	CcSEcCtD
Salmeterol—Oropharyngeal discomfort—Lomustine—brain cancer	0.00938	0.029	CcSEcCtD
Salmeterol—Contusion—Lomustine—brain cancer	0.00782	0.0241	CcSEcCtD
Salmeterol—Oropharyngeal pain—Lomustine—brain cancer	0.0075	0.0232	CcSEcCtD
Salmeterol—Dysphonia—Procarbazine—brain cancer	0.00526	0.0162	CcSEcCtD
Salmeterol—Oral candidiasis—Carmustine—brain cancer	0.00427	0.0132	CcSEcCtD
Salmeterol—Oral candidiasis—Temozolomide—brain cancer	0.00412	0.0127	CcSEcCtD
Salmeterol—Tenderness—Hydroxyurea—brain cancer	0.00384	0.0119	CcSEcCtD
Salmeterol—Endocrine disorder—Temozolomide—brain cancer	0.00316	0.00975	CcSEcCtD
Salmeterol—Viral infection—Temozolomide—brain cancer	0.0029	0.00895	CcSEcCtD
Salmeterol—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—CYP2C9—brain cancer	0.00285	0.0842	CbGpPWpGaD
Salmeterol—Laryngospasm—Etoposide—brain cancer	0.00281	0.00866	CcSEcCtD
Salmeterol—Infection—Carboplatin—brain cancer	0.00276	0.00853	CcSEcCtD
Salmeterol—Neck pain—Carmustine—brain cancer	0.00274	0.00846	CcSEcCtD
Salmeterol—Musculoskeletal pain—Temozolomide—brain cancer	0.00265	0.00818	CcSEcCtD
Salmeterol—Candida infection—Carmustine—brain cancer	0.00259	0.00798	CcSEcCtD
Salmeterol—CYP2C8—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP2C9—brain cancer	0.00256	0.0757	CbGpPWpGaD
Salmeterol—Candida infection—Temozolomide—brain cancer	0.0025	0.00772	CcSEcCtD
Salmeterol—Pneumonia—Procarbazine—brain cancer	0.00244	0.00752	CcSEcCtD
Salmeterol—Infection—Lomustine—brain cancer	0.00242	0.00746	CcSEcCtD
Salmeterol—Pain—Carboplatin—brain cancer	0.00238	0.00734	CcSEcCtD
Salmeterol—Chest discomfort—Etoposide—brain cancer	0.00237	0.00731	CcSEcCtD
Salmeterol—CYP2C8—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP2C9—brain cancer	0.00233	0.0689	CbGpPWpGaD
Salmeterol—Epistaxis—Procarbazine—brain cancer	0.00229	0.00705	CcSEcCtD
Salmeterol—Swelling—Carmustine—brain cancer	0.00223	0.00688	CcSEcCtD
Salmeterol—Ear pain—Temozolomide—brain cancer	0.00223	0.00688	CcSEcCtD
Salmeterol—Body temperature increased—Carboplatin—brain cancer	0.0022	0.00679	CcSEcCtD
Salmeterol—Inflammation—Etoposide—brain cancer	0.00216	0.00667	CcSEcCtD
Salmeterol—Gastroenteritis—Temozolomide—brain cancer	0.00214	0.00662	CcSEcCtD
Salmeterol—Injury—Carmustine—brain cancer	0.00214	0.0066	CcSEcCtD
Salmeterol—Nasal congestion—Temozolomide—brain cancer	0.00209	0.00644	CcSEcCtD
Salmeterol—Candida infection—Etoposide—brain cancer	0.002	0.00617	CcSEcCtD
Salmeterol—CYP2C8—CYP2E1 reactions—CYP2C9—brain cancer	0.00198	0.0587	CbGpPWpGaD
Salmeterol—CYP3A7—Xenobiotics—CYP2C9—brain cancer	0.00196	0.0581	CbGpPWpGaD
Salmeterol—Arrhythmia—Procarbazine—brain cancer	0.00194	0.006	CcSEcCtD
Salmeterol—Body temperature increased—Lomustine—brain cancer	0.00192	0.00594	CcSEcCtD
Salmeterol—Infestation NOS—Hydroxyurea—brain cancer	0.00188	0.00579	CcSEcCtD
Salmeterol—Infestation—Hydroxyurea—brain cancer	0.00188	0.00579	CcSEcCtD
Salmeterol—Tension—Procarbazine—brain cancer	0.00186	0.00573	CcSEcCtD
Salmeterol—Nervousness—Procarbazine—brain cancer	0.00184	0.00568	CcSEcCtD
Salmeterol—Propafenone—CYP2C9—brain cancer	0.0018	1	CrCbGaD
Salmeterol—Tremor—Procarbazine—brain cancer	0.00177	0.00547	CcSEcCtD
Salmeterol—Swelling—Etoposide—brain cancer	0.00172	0.00532	CcSEcCtD
Salmeterol—Cough—Procarbazine—brain cancer	0.00165	0.0051	CcSEcCtD
Salmeterol—Hypertension—Procarbazine—brain cancer	0.00163	0.00505	CcSEcCtD
Salmeterol—Myalgia—Procarbazine—brain cancer	0.00161	0.00497	CcSEcCtD
Salmeterol—Arthralgia—Procarbazine—brain cancer	0.00161	0.00497	CcSEcCtD
Salmeterol—Anxiety—Procarbazine—brain cancer	0.00161	0.00496	CcSEcCtD
Salmeterol—Bronchitis—Temozolomide—brain cancer	0.00158	0.00488	CcSEcCtD
Salmeterol—Dry mouth—Procarbazine—brain cancer	0.00158	0.00487	CcSEcCtD
Salmeterol—Vomiting—Lomustine—brain cancer	0.00155	0.00478	CcSEcCtD
Salmeterol—Oedema—Procarbazine—brain cancer	0.00155	0.00477	CcSEcCtD
Salmeterol—Infection—Procarbazine—brain cancer	0.00154	0.00474	CcSEcCtD
Salmeterol—Hyperglycaemia—Carmustine—brain cancer	0.00153	0.00473	CcSEcCtD
Salmeterol—Upper respiratory tract infection—Temozolomide—brain cancer	0.00153	0.00471	CcSEcCtD
Salmeterol—Pneumonia—Carmustine—brain cancer	0.00152	0.00471	CcSEcCtD
Salmeterol—Tachycardia—Procarbazine—brain cancer	0.00151	0.00465	CcSEcCtD
Salmeterol—Hyperglycaemia—Temozolomide—brain cancer	0.00148	0.00457	CcSEcCtD
Salmeterol—Urinary tract infection—Carmustine—brain cancer	0.00147	0.00455	CcSEcCtD
Salmeterol—Pneumonia—Temozolomide—brain cancer	0.00147	0.00455	CcSEcCtD
Salmeterol—Infestation—Temozolomide—brain cancer	0.00146	0.00452	CcSEcCtD
Salmeterol—Infestation NOS—Temozolomide—brain cancer	0.00146	0.00452	CcSEcCtD
Salmeterol—Nausea—Lomustine—brain cancer	0.00145	0.00446	CcSEcCtD
Salmeterol—Urinary tract infection—Temozolomide—brain cancer	0.00142	0.00439	CcSEcCtD
Salmeterol—CYP3A5—Xenobiotics—CYP2C9—brain cancer	0.00142	0.042	CbGpPWpGaD
Salmeterol—Musculoskeletal discomfort—Procarbazine—brain cancer	0.00141	0.00435	CcSEcCtD
Salmeterol—Insomnia—Procarbazine—brain cancer	0.0014	0.00431	CcSEcCtD
Salmeterol—Paraesthesia—Procarbazine—brain cancer	0.00139	0.00428	CcSEcCtD
Salmeterol—Sinusitis—Temozolomide—brain cancer	0.00137	0.00424	CcSEcCtD
Salmeterol—Cramp muscle—Etoposide—brain cancer	0.00137	0.00423	CcSEcCtD
Salmeterol—CYP3A5—Tamoxifen metabolism—CYP2C9—brain cancer	0.00136	0.0404	CbGpPWpGaD
Salmeterol—Ill-defined disorder—Hydroxyurea—brain cancer	0.00136	0.0042	CcSEcCtD
Salmeterol—Connective tissue disorder—Carmustine—brain cancer	0.00134	0.00413	CcSEcCtD
Salmeterol—Fatigue—Procarbazine—brain cancer	0.00133	0.00411	CcSEcCtD
Salmeterol—Malaise—Hydroxyurea—brain cancer	0.00132	0.00408	CcSEcCtD
Salmeterol—Constipation—Procarbazine—brain cancer	0.00132	0.00408	CcSEcCtD
Salmeterol—Pain—Procarbazine—brain cancer	0.00132	0.00408	CcSEcCtD
Salmeterol—Pharyngitis—Temozolomide—brain cancer	0.00131	0.00403	CcSEcCtD
Salmeterol—Bronchospasm—Etoposide—brain cancer	0.00129	0.00399	CcSEcCtD
Salmeterol—Connective tissue disorder—Temozolomide—brain cancer	0.00129	0.00399	CcSEcCtD
Salmeterol—Feeling abnormal—Procarbazine—brain cancer	0.00127	0.00393	CcSEcCtD
Salmeterol—Gastrointestinal pain—Procarbazine—brain cancer	0.00126	0.0039	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.00124	0.00382	CcSEcCtD
Salmeterol—Discomfort—Hydroxyurea—brain cancer	0.00123	0.0038	CcSEcCtD
Salmeterol—CYP2C8—Xenobiotics—CYP2C9—brain cancer	0.00123	0.0364	CbGpPWpGaD
Salmeterol—Urticaria—Procarbazine—brain cancer	0.00123	0.00379	CcSEcCtD
Salmeterol—Abdominal pain—Procarbazine—brain cancer	0.00122	0.00377	CcSEcCtD
Salmeterol—Body temperature increased—Procarbazine—brain cancer	0.00122	0.00377	CcSEcCtD
Salmeterol—Cardiac disorder—Temozolomide—brain cancer	0.00122	0.00377	CcSEcCtD
Salmeterol—Arrhythmia—Carmustine—brain cancer	0.00122	0.00375	CcSEcCtD
Salmeterol—Oedema—Hydroxyurea—brain cancer	0.0012	0.00369	CcSEcCtD
Salmeterol—Mental disorder—Carmustine—brain cancer	0.00119	0.00368	CcSEcCtD
Salmeterol—Infection—Hydroxyurea—brain cancer	0.00119	0.00367	CcSEcCtD
Salmeterol—Immune system disorder—Temozolomide—brain cancer	0.00119	0.00367	CcSEcCtD
Salmeterol—Mediastinal disorder—Temozolomide—brain cancer	0.00119	0.00366	CcSEcCtD
Salmeterol—Malnutrition—Carmustine—brain cancer	0.00118	0.00366	CcSEcCtD
Salmeterol—CYP2C8—Tamoxifen metabolism—CYP2C9—brain cancer	0.00118	0.035	CbGpPWpGaD
Salmeterol—Pneumonia—Etoposide—brain cancer	0.00118	0.00364	CcSEcCtD
Salmeterol—Nervous system disorder—Hydroxyurea—brain cancer	0.00117	0.00362	CcSEcCtD
Salmeterol—Infestation—Etoposide—brain cancer	0.00117	0.00362	CcSEcCtD
Salmeterol—Infestation NOS—Etoposide—brain cancer	0.00117	0.00362	CcSEcCtD
Salmeterol—Skin disorder—Hydroxyurea—brain cancer	0.00116	0.00359	CcSEcCtD
Salmeterol—Mental disorder—Temozolomide—brain cancer	0.00115	0.00356	CcSEcCtD
Salmeterol—Back pain—Carmustine—brain cancer	0.00115	0.00354	CcSEcCtD
Salmeterol—Malnutrition—Temozolomide—brain cancer	0.00114	0.00353	CcSEcCtD
Salmeterol—Hypersensitivity—Procarbazine—brain cancer	0.00114	0.00351	CcSEcCtD
Salmeterol—Tremor—Carmustine—brain cancer	0.00111	0.00343	CcSEcCtD
Salmeterol—Asthenia—Procarbazine—brain cancer	0.00111	0.00342	CcSEcCtD
Salmeterol—Back pain—Temozolomide—brain cancer	0.00111	0.00342	CcSEcCtD
Salmeterol—Agitation—Carmustine—brain cancer	0.00109	0.00336	CcSEcCtD
Salmeterol—Tremor—Temozolomide—brain cancer	0.00107	0.00331	CcSEcCtD
Salmeterol—Dyspnoea—Hydroxyurea—brain cancer	0.00107	0.00329	CcSEcCtD
Salmeterol—Ill-defined disorder—Temozolomide—brain cancer	0.00106	0.00328	CcSEcCtD
Salmeterol—Diarrhoea—Procarbazine—brain cancer	0.00106	0.00326	CcSEcCtD
Salmeterol—Dyspepsia—Hydroxyurea—brain cancer	0.00105	0.00325	CcSEcCtD
Salmeterol—Agitation—Temozolomide—brain cancer	0.00105	0.00325	CcSEcCtD
Salmeterol—Angioedema—Temozolomide—brain cancer	0.00105	0.00323	CcSEcCtD
Salmeterol—Malaise—Temozolomide—brain cancer	0.00103	0.00319	CcSEcCtD
Salmeterol—Fatigue—Hydroxyurea—brain cancer	0.00103	0.00318	CcSEcCtD
Salmeterol—Hypertension—Carmustine—brain cancer	0.00102	0.00316	CcSEcCtD
Salmeterol—Pain—Hydroxyurea—brain cancer	0.00102	0.00316	CcSEcCtD
Salmeterol—Constipation—Hydroxyurea—brain cancer	0.00102	0.00316	CcSEcCtD
Salmeterol—Dizziness—Procarbazine—brain cancer	0.00102	0.00315	CcSEcCtD
Salmeterol—Palpitations—Temozolomide—brain cancer	0.00101	0.00312	CcSEcCtD
Salmeterol—Myalgia—Carmustine—brain cancer	0.00101	0.00311	CcSEcCtD
Salmeterol—Chest pain—Carmustine—brain cancer	0.00101	0.00311	CcSEcCtD
Salmeterol—Anxiety—Carmustine—brain cancer	0.00101	0.0031	CcSEcCtD
Salmeterol—Cough—Temozolomide—brain cancer	0.000999	0.00308	CcSEcCtD
Salmeterol—Hypertension—Temozolomide—brain cancer	0.000988	0.00305	CcSEcCtD
Salmeterol—Feeling abnormal—Hydroxyurea—brain cancer	0.000986	0.00304	CcSEcCtD
Salmeterol—Vomiting—Procarbazine—brain cancer	0.000983	0.00303	CcSEcCtD
Salmeterol—Cardiac disorder—Etoposide—brain cancer	0.000977	0.00301	CcSEcCtD
Salmeterol—Arthralgia—Temozolomide—brain cancer	0.000975	0.00301	CcSEcCtD
Salmeterol—Myalgia—Temozolomide—brain cancer	0.000975	0.00301	CcSEcCtD
Salmeterol—Rash—Procarbazine—brain cancer	0.000974	0.00301	CcSEcCtD
Salmeterol—CYP3A5—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.000974	0.0288	CbGpPWpGaD
Salmeterol—Dermatitis—Procarbazine—brain cancer	0.000973	0.003	CcSEcCtD
Salmeterol—Anxiety—Temozolomide—brain cancer	0.000971	0.003	CcSEcCtD
Salmeterol—Headache—Procarbazine—brain cancer	0.000968	0.00299	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.000968	0.00299	CcSEcCtD
Salmeterol—Oedema—Carmustine—brain cancer	0.000967	0.00298	CcSEcCtD
Salmeterol—Discomfort—Temozolomide—brain cancer	0.000963	0.00297	CcSEcCtD
Salmeterol—Infection—Carmustine—brain cancer	0.00096	0.00296	CcSEcCtD
Salmeterol—Dry mouth—Temozolomide—brain cancer	0.000953	0.00294	CcSEcCtD
Salmeterol—Immune system disorder—Etoposide—brain cancer	0.000951	0.00293	CcSEcCtD
Salmeterol—Mediastinal disorder—Etoposide—brain cancer	0.000948	0.00293	CcSEcCtD
Salmeterol—Body temperature increased—Hydroxyurea—brain cancer	0.000945	0.00292	CcSEcCtD
Salmeterol—Tachycardia—Carmustine—brain cancer	0.000944	0.00291	CcSEcCtD
Salmeterol—Anaphylactic shock—Temozolomide—brain cancer	0.000934	0.00288	CcSEcCtD
Salmeterol—Oedema—Temozolomide—brain cancer	0.000934	0.00288	CcSEcCtD
Salmeterol—Infection—Temozolomide—brain cancer	0.000928	0.00286	CcSEcCtD
Salmeterol—Nausea—Procarbazine—brain cancer	0.000918	0.00283	CcSEcCtD
Salmeterol—Nervous system disorder—Temozolomide—brain cancer	0.000916	0.00283	CcSEcCtD
Salmeterol—Skin disorder—Temozolomide—brain cancer	0.000908	0.0028	CcSEcCtD
Salmeterol—Back pain—Etoposide—brain cancer	0.000886	0.00273	CcSEcCtD
Salmeterol—Hypersensitivity—Hydroxyurea—brain cancer	0.000881	0.00272	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Carmustine—brain cancer	0.000881	0.00272	CcSEcCtD
Salmeterol—Muscle spasms—Etoposide—brain cancer	0.000881	0.00272	CcSEcCtD
Salmeterol—Insomnia—Carmustine—brain cancer	0.000874	0.0027	CcSEcCtD
Salmeterol—Paraesthesia—Carmustine—brain cancer	0.000868	0.00268	CcSEcCtD
Salmeterol—Dyspnoea—Carmustine—brain cancer	0.000862	0.00266	CcSEcCtD
Salmeterol—Asthenia—Hydroxyurea—brain cancer	0.000858	0.00265	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Temozolomide—brain cancer	0.000851	0.00263	CcSEcCtD
Salmeterol—Ill-defined disorder—Etoposide—brain cancer	0.00085	0.00262	CcSEcCtD
Salmeterol—Insomnia—Temozolomide—brain cancer	0.000845	0.00261	CcSEcCtD
Salmeterol—Paraesthesia—Temozolomide—brain cancer	0.000839	0.00259	CcSEcCtD
Salmeterol—Dyspnoea—Temozolomide—brain cancer	0.000833	0.00257	CcSEcCtD
Salmeterol—Constipation—Carmustine—brain cancer	0.000827	0.00255	CcSEcCtD
Salmeterol—Pain—Carmustine—brain cancer	0.000827	0.00255	CcSEcCtD
Salmeterol—Malaise—Etoposide—brain cancer	0.000826	0.00255	CcSEcCtD
Salmeterol—Dyspepsia—Temozolomide—brain cancer	0.000822	0.00254	CcSEcCtD
Salmeterol—Diarrhoea—Hydroxyurea—brain cancer	0.000818	0.00253	CcSEcCtD
Salmeterol—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000815	0.0241	CbGpPWpGaD
Salmeterol—Fatigue—Temozolomide—brain cancer	0.000806	0.00249	CcSEcCtD
Salmeterol—CYP3A7—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000804	0.0238	CbGpPWpGaD
Salmeterol—Cough—Etoposide—brain cancer	0.000799	0.00247	CcSEcCtD
Salmeterol—Constipation—Temozolomide—brain cancer	0.000799	0.00247	CcSEcCtD
Salmeterol—Pain—Temozolomide—brain cancer	0.000799	0.00247	CcSEcCtD
Salmeterol—Feeling abnormal—Carmustine—brain cancer	0.000797	0.00246	CcSEcCtD
Salmeterol—Hypertension—Etoposide—brain cancer	0.000791	0.00244	CcSEcCtD
Salmeterol—Dizziness—Hydroxyurea—brain cancer	0.000791	0.00244	CcSEcCtD
Salmeterol—Gastrointestinal pain—Carmustine—brain cancer	0.000791	0.00244	CcSEcCtD
Salmeterol—Chest pain—Etoposide—brain cancer	0.00078	0.00241	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.000775	0.00239	CcSEcCtD
Salmeterol—Discomfort—Etoposide—brain cancer	0.000771	0.00238	CcSEcCtD
Salmeterol—Feeling abnormal—Temozolomide—brain cancer	0.00077	0.00238	CcSEcCtD
Salmeterol—Abdominal pain—Carmustine—brain cancer	0.000764	0.00236	CcSEcCtD
Salmeterol—Body temperature increased—Carmustine—brain cancer	0.000764	0.00236	CcSEcCtD
Salmeterol—Gastrointestinal pain—Temozolomide—brain cancer	0.000764	0.00236	CcSEcCtD
Salmeterol—Vomiting—Hydroxyurea—brain cancer	0.00076	0.00235	CcSEcCtD
Salmeterol—Rash—Hydroxyurea—brain cancer	0.000754	0.00233	CcSEcCtD
Salmeterol—Dermatitis—Hydroxyurea—brain cancer	0.000753	0.00233	CcSEcCtD
Salmeterol—Headache—Hydroxyurea—brain cancer	0.000749	0.00231	CcSEcCtD
Salmeterol—Anaphylactic shock—Etoposide—brain cancer	0.000748	0.00231	CcSEcCtD
Salmeterol—Infection—Etoposide—brain cancer	0.000743	0.00229	CcSEcCtD
Salmeterol—Urticaria—Temozolomide—brain cancer	0.000742	0.00229	CcSEcCtD
Salmeterol—Abdominal pain—Temozolomide—brain cancer	0.000739	0.00228	CcSEcCtD
Salmeterol—Body temperature increased—Temozolomide—brain cancer	0.000739	0.00228	CcSEcCtD
Salmeterol—Tachycardia—Etoposide—brain cancer	0.00073	0.00225	CcSEcCtD
Salmeterol—Skin disorder—Etoposide—brain cancer	0.000726	0.00224	CcSEcCtD
Salmeterol—Hypersensitivity—Carmustine—brain cancer	0.000712	0.0022	CcSEcCtD
Salmeterol—Nausea—Hydroxyurea—brain cancer	0.00071	0.00219	CcSEcCtD
Salmeterol—Asthenia—Carmustine—brain cancer	0.000694	0.00214	CcSEcCtD
Salmeterol—Hypersensitivity—Temozolomide—brain cancer	0.000688	0.00212	CcSEcCtD
Salmeterol—Paraesthesia—Etoposide—brain cancer	0.000671	0.00207	CcSEcCtD
Salmeterol—Asthenia—Temozolomide—brain cancer	0.00067	0.00207	CcSEcCtD
Salmeterol—Dyspnoea—Etoposide—brain cancer	0.000667	0.00206	CcSEcCtD
Salmeterol—Diarrhoea—Carmustine—brain cancer	0.000662	0.00204	CcSEcCtD
Salmeterol—CYP3A7—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000661	0.0195	CbGpPWpGaD
Salmeterol—CYP3A4—Xenobiotics—CYP2C9—brain cancer	0.00066	0.0195	CbGpPWpGaD
Salmeterol—Fatigue—Etoposide—brain cancer	0.000645	0.00199	CcSEcCtD
Salmeterol—Dizziness—Carmustine—brain cancer	0.000639	0.00197	CcSEcCtD
Salmeterol—Pain—Etoposide—brain cancer	0.000639	0.00197	CcSEcCtD
Salmeterol—Constipation—Etoposide—brain cancer	0.000639	0.00197	CcSEcCtD
Salmeterol—Diarrhoea—Temozolomide—brain cancer	0.000639	0.00197	CcSEcCtD
Salmeterol—CYP3A4—Tamoxifen metabolism—CYP2C9—brain cancer	0.000634	0.0188	CbGpPWpGaD
Salmeterol—Dizziness—Temozolomide—brain cancer	0.000618	0.00191	CcSEcCtD
Salmeterol—Feeling abnormal—Etoposide—brain cancer	0.000616	0.0019	CcSEcCtD
Salmeterol—Vomiting—Carmustine—brain cancer	0.000615	0.0019	CcSEcCtD
Salmeterol—Gastrointestinal pain—Etoposide—brain cancer	0.000611	0.00189	CcSEcCtD
Salmeterol—Rash—Carmustine—brain cancer	0.00061	0.00188	CcSEcCtD
Salmeterol—Dermatitis—Carmustine—brain cancer	0.000609	0.00188	CcSEcCtD
Salmeterol—Headache—Carmustine—brain cancer	0.000606	0.00187	CcSEcCtD
Salmeterol—Vomiting—Temozolomide—brain cancer	0.000594	0.00183	CcSEcCtD
Salmeterol—Urticaria—Etoposide—brain cancer	0.000594	0.00183	CcSEcCtD
Salmeterol—Body temperature increased—Etoposide—brain cancer	0.000591	0.00182	CcSEcCtD
Salmeterol—Abdominal pain—Etoposide—brain cancer	0.000591	0.00182	CcSEcCtD
Salmeterol—CYP2C8—Arachidonic acid metabolism—CYP2C9—brain cancer	0.00059	0.0175	CbGpPWpGaD
Salmeterol—Rash—Temozolomide—brain cancer	0.000589	0.00182	CcSEcCtD
Salmeterol—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000589	0.0174	CbGpPWpGaD
Salmeterol—Dermatitis—Temozolomide—brain cancer	0.000589	0.00182	CcSEcCtD
Salmeterol—Headache—Temozolomide—brain cancer	0.000585	0.00181	CcSEcCtD
Salmeterol—CYP3A5—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000581	0.0172	CbGpPWpGaD
Salmeterol—Nausea—Carmustine—brain cancer	0.000574	0.00177	CcSEcCtD
Salmeterol—Nausea—Temozolomide—brain cancer	0.000555	0.00171	CcSEcCtD
Salmeterol—Hypersensitivity—Etoposide—brain cancer	0.000551	0.0017	CcSEcCtD
Salmeterol—Asthenia—Etoposide—brain cancer	0.000536	0.00166	CcSEcCtD
Salmeterol—Diarrhoea—Etoposide—brain cancer	0.000512	0.00158	CcSEcCtD
Salmeterol—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.00051	0.0151	CbGpPWpGaD
Salmeterol—CYP2C8—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000504	0.0149	CbGpPWpGaD
Salmeterol—CYP3A5—Irinotecan Pathway—APC—brain cancer	0.0005	0.0148	CbGpPWpGaD
Salmeterol—Dizziness—Etoposide—brain cancer	0.000494	0.00153	CcSEcCtD
Salmeterol—CYP3A5—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000478	0.0141	CbGpPWpGaD
Salmeterol—Vomiting—Etoposide—brain cancer	0.000475	0.00147	CcSEcCtD
Salmeterol—Rash—Etoposide—brain cancer	0.000471	0.00145	CcSEcCtD
Salmeterol—Dermatitis—Etoposide—brain cancer	0.000471	0.00145	CcSEcCtD
Salmeterol—Headache—Etoposide—brain cancer	0.000468	0.00145	CcSEcCtD
Salmeterol—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.000453	0.0134	CbGpPWpGaD
Salmeterol—Nausea—Etoposide—brain cancer	0.000444	0.00137	CcSEcCtD
Salmeterol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.000431	0.0128	CbGpPWpGaD
Salmeterol—CYP2C8—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000414	0.0122	CbGpPWpGaD
Salmeterol—CYP3A7—Biological oxidations—CYP2C9—brain cancer	0.000351	0.0104	CbGpPWpGaD
Salmeterol—CYP3A7—Metapathway biotransformation—CYP2C9—brain cancer	0.000346	0.0102	CbGpPWpGaD
Salmeterol—ADRB2—GPCRs, Other—SMO—brain cancer	0.000328	0.00972	CbGpPWpGaD
Salmeterol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000274	0.0081	CbGpPWpGaD
Salmeterol—CYP3A4—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.00027	0.008	CbGpPWpGaD
Salmeterol—CYP3A5—Biological oxidations—CYP2C9—brain cancer	0.000254	0.00751	CbGpPWpGaD
Salmeterol—CYP3A5—Metapathway biotransformation—CYP2C9—brain cancer	0.00025	0.0074	CbGpPWpGaD
Salmeterol—CYP3A4—Irinotecan Pathway—APC—brain cancer	0.000233	0.00688	CbGpPWpGaD
Salmeterol—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000222	0.00657	CbGpPWpGaD
Salmeterol—CYP2C8—Biological oxidations—CYP2C9—brain cancer	0.00022	0.0065	CbGpPWpGaD
Salmeterol—CYP2C8—Metapathway biotransformation—CYP2C9—brain cancer	0.000217	0.00641	CbGpPWpGaD
Salmeterol—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—brain cancer	0.000206	0.0061	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—PTCH2—brain cancer	0.000191	0.00564	CbGpPWpGaD
Salmeterol—ADRB2—Arf6 signaling events—EGFR—brain cancer	0.000184	0.00544	CbGpPWpGaD
Salmeterol—ADRB2—Arf6 trafficking events—CTNNB1—brain cancer	0.000183	0.00542	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—OR4C12—brain cancer	0.000167	0.00495	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—OR14C36—brain cancer	0.000167	0.00495	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—OR14C36—brain cancer	0.000152	0.00449	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—OR4C12—brain cancer	0.000152	0.00449	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—CYP2C9—brain cancer	0.000118	0.00349	CbGpPWpGaD
Salmeterol—CYP3A4—Metapathway biotransformation—CYP2C9—brain cancer	0.000116	0.00344	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—SHH—brain cancer	9.82e-05	0.00291	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PTCH2—brain cancer	9.78e-05	0.00289	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—SMO—brain cancer	9.31e-05	0.00275	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—PTCH1—brain cancer	9.31e-05	0.00275	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—OR14C36—brain cancer	8.97e-05	0.00265	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—OR4C12—brain cancer	8.97e-05	0.00265	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—ABR—brain cancer	8.45e-05	0.0025	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	8.44e-05	0.0025	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—ABR—brain cancer	7.68e-05	0.00227	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—DTX2—brain cancer	7.63e-05	0.00226	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—IDH1—brain cancer	6.17e-05	0.00183	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CYP2C9—brain cancer	6e-05	0.00178	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PTCH2—brain cancer	5.78e-05	0.00171	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HES5—brain cancer	5.6e-05	0.00166	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—STRADA—brain cancer	5.43e-05	0.00161	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—TRPC6—brain cancer	5.35e-05	0.00158	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—BSG—brain cancer	5.1e-05	0.00151	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—SHH—brain cancer	5.04e-05	0.00149	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—TRPC6—brain cancer	4.86e-05	0.00144	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PTCH1—brain cancer	4.78e-05	0.00141	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—SMO—brain cancer	4.78e-05	0.00141	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ABR—brain cancer	4.53e-05	0.00134	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—IDH1—brain cancer	4.39e-05	0.0013	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—GLI2—brain cancer	4.38e-05	0.0013	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP2C9—brain cancer	4.34e-05	0.00128	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—GLI1—brain cancer	4.12e-05	0.00122	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—VAV1—brain cancer	4.01e-05	0.00119	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—SUFU—brain cancer	3.9e-05	0.00116	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—GFAP—brain cancer	3.77e-05	0.00111	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP2C9—brain cancer	3.76e-05	0.00111	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—BSG—brain cancer	3.69e-05	0.00109	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—VAV1—brain cancer	3.64e-05	0.00108	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HEY1—brain cancer	3.57e-05	0.00106	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—DLL1—brain cancer	3.5e-05	0.00104	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ENO2—brain cancer	3.47e-05	0.00103	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—BSG—brain cancer	3.19e-05	0.000945	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—IDH1—brain cancer	3.17e-05	0.000939	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—SHH—brain cancer	2.98e-05	0.000881	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TRPC6—brain cancer	2.87e-05	0.000849	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—SMO—brain cancer	2.82e-05	0.000835	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PTCH1—brain cancer	2.82e-05	0.000835	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—IDH1—brain cancer	2.75e-05	0.000813	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—PIK3CG—brain cancer	2.55e-05	0.000753	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ENO2—brain cancer	2.51e-05	0.000742	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PIK3CG—brain cancer	2.31e-05	0.000684	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NOTCH2—brain cancer	2.26e-05	0.000668	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	2.24e-05	0.000662	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ENO2—brain cancer	2.17e-05	0.000643	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—VAV1—brain cancer	2.15e-05	0.000636	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP2C9—brain cancer	2.02e-05	0.000597	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HES1—brain cancer	1.85e-05	0.000547	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—IL2—brain cancer	1.79e-05	0.00053	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PDGFRA—brain cancer	1.76e-05	0.000521	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—BSG—brain cancer	1.71e-05	0.000507	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—SPP1—brain cancer	1.71e-05	0.000506	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—IL2—brain cancer	1.63e-05	0.000481	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PIK3CG—brain cancer	1.59e-05	0.000471	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IRS2—brain cancer	1.55e-05	0.000458	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—IDH1—brain cancer	1.47e-05	0.000436	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—APC—brain cancer	1.37e-05	0.000404	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PIK3CG—brain cancer	1.37e-05	0.000404	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—EGFR—brain cancer	1.24e-05	0.000368	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ENO2—brain cancer	1.17e-05	0.000345	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PIK3CG—brain cancer	1.15e-05	0.00034	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—RELA—brain cancer	1.07e-05	0.000316	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ERBB2—brain cancer	1.06e-05	0.000314	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PIK3CG—brain cancer	9.96e-06	0.000295	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IL2—brain cancer	9.61e-06	0.000284	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CCND1—brain cancer	9.37e-06	0.000277	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CTNNB1—brain cancer	9.28e-06	0.000275	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—VEGFA—brain cancer	8.17e-06	0.000242	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—STAT3—brain cancer	8.09e-06	0.000239	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MYC—brain cancer	7.51e-06	0.000222	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—EGFR—brain cancer	7.35e-06	0.000218	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TP53—brain cancer	6.17e-06	0.000183	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PIK3CG—brain cancer	5.35e-06	0.000158	CbGpPWpGaD
